Explore Tesofensine dosage trends, dilution volumes, and vial size patterns from anonymized WPA calculator sessions.
Tesofensine is a triple monoamine reuptake inhibitor that blocks the reabsorption of noradrenaline, dopamine, and serotonin, originally investigated for neurodegenerative disease and later studied for its appetite-suppressing weight-loss effects. It is dosed at the mcg level once daily and is available in both injectable and capsule research formats. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when preparing Tesofensine.
Tesofensine is an oral triple monoamine reuptake inhibitor (a small molecule, not a peptide) studied for obesity after large Phase 2 weight loss, sourced in research for appetite and weight work. It ships as capsules or a powder.
Tesofensine inhibits the presynaptic reuptake transporters for dopamine, noradrenaline, and serotonin, raising synaptic monoamine levels throughout the central nervous system. The weight-loss effect is hypothesized to derive primarily from increased noradrenaline tone in hypothalamic appetite circuits and increased dopaminergic reward signalling that reduces drive to overeat, rather than from incretin-style hormonal slowing of gastric emptying. Cardiovascular safety (heart rate, blood pressure elevation) is the dominant concern of the mechanism.
Astrup et al. (Lancet 2008) reported the foundational Phase 2 trial: 0.25mg, 0.5mg, and 1.0mg daily doses produced mean weight losses of 6.7%, 11.3%, and 12.8% at 24 weeks respectively, versus 2.0% on placebo, in adults with obesity on a hypocaloric diet. A 2010 follow-up characterised energy-expenditure and appetite-suppression contributions. Saniona's Phase 3 program in Mexico (the only jurisdiction where tesofensine has reached commercial approval, marketed as Tesomet) supported the 2023 Mexican COFEPRIS approval for chronic weight management. Tesofensine is not approved by the FDA or EMA.
Tesofensine has a reported half-life of ~9 days, and the dose intervals researchers model most often fall around once daily. A very long half-life means tesofensine accumulates substantially over weeks of daily dosing before reaching steady state — a single missed dose has almost no effect on levels. It is catalogued under Weight Loss on WPA.
The WPA community has not yet logged enough Tesofensine calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.